当前位置:循环首页>正文

[OCC2009]Transcatheter Interventional Replacement of Pulmonic Valve Using Percutaneous Heart Valve

Qi-Ling Cao, Rush University Medical Center, USA

作者:  曹其龄   日期:2009/5/27 13:39:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

Surgically placed valve conduits in the pulmonic position often require multiple reoperations. Percutaneous replacement of the pulmonic valve is an attractive option to provide relief of patient symptoms, improve hemodynamic function, and avoid the mortality and morbidity of repeat open heart surgeries. We report on the initial results of an FDA approved feasibility study of a percutaneous placement of the Edwards Sapien?Percutaneous Heart Valve (PHV) in the pulmonic position.

    Surgically placed valve conduits in the pulmonic position often require multiple reoperations. Percutaneous replacement of the pulmonic valve is an attractive option to provide relief of patient symptoms, improve hemodynamic function, and avoid the mortality and morbidity of repeat open heart surgeries. We report on the initial results of an FDA approved feasibility study of a percutaneous placement of the Edwards Sapien™ Percutaneous Heart Valve (PHV) in the pulmonic position.

    Between April-December 2008, 11 patients (8 males/3 females) with a regurgitant and/or stenotic pulmonary valve conduit underwent transcatheter insertion of the 23 (10 patients) or 26 mm Edwards Sapien™ PHV into the pulmonic position using a 24-26 Fr percutaneous femoral venous sheath. Patient age ranged from 14-71 yrs. 8/11 patients had previously undergone placement of a stent in the pulmonic conduit to relieve significant conduit obstruction and therefore had severe pulmonic regurgitation (PR). At cath, the mean gradient across the stent pre-intervention was 37.5±7.6 mm Hg. 10/11 (91%) valves were successfully delivered using an antegrade percutaneous technique. One valve could not be properly seated, requiring surgical removal, and a 26 mm valve was implanted using the “perventricular” technique (both performed without bypass). There were no deaths or adverse events within 30 days. Gradient across the valve decreased to a mean of 16.4±7.6 mm Hg. All 11 patients demonstrated improved valve function (decrease in PR to mild or less) on immediate post-implantation angiography and intracardiac echocardiograhy. At 30-day follow-up, all patients reported improvement in symptoms. By transthoracic echocardiogram, the mean gradient across the valve was 22.6±11.6 mmHg. There was trivial or mild PR in 4 patients and the rest had no PR.

    Our initial experience using the Edwards Sapien™ PHV demonstrates the procedure to be safe and effective in subjects with regurgitant/stenotic pulmonary valve conduits. Further patient enrollment and clinical follow-up is ongoing to adequately assess functional improvement, freedom from adverse cardiac events, and longevity of the implanted valve.

 

版面编辑:张家程


结构性心脏病

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530